Last Updated: November 17, 2026

TLANDO Drug Patent Profile

« Back to Dashboard


Which patents cover Tlando, and when can generic versions of Tlando launch?

Tlando is a drug marketed by Verity and is included in one NDA. There are fifteen patents protecting this drug.

The generic ingredient in TLANDO is testosterone undecanoate. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.

DrugPatentWatch® Generic Entry Outlook for Tlando

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 8, 2029. This may change due to patent challenges or generic licensing.

There is one tentative approval for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for TLANDO?
  • What are the global sales for TLANDO?
  • What is Average Wholesale Price for TLANDO?
Summary for TLANDO
US Patents:15
Applicants:1
NDAs:1

US Patents and Regulatory Information for TLANDO

TLANDO is protected by sixteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TLANDO is ⤷  Start Trial.

This potential generic entry date is based on patent ⤷  Start Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Verity TLANDO testosterone undecanoate CAPSULE;ORAL 208088-001 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Verity TLANDO testosterone undecanoate CAPSULE;ORAL 208088-001 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Verity TLANDO testosterone undecanoate CAPSULE;ORAL 208088-001 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Verity TLANDO testosterone undecanoate CAPSULE;ORAL 208088-001 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Verity TLANDO testosterone undecanoate CAPSULE;ORAL 208088-001 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TLANDO

When does loss-of-exclusivity occur for TLANDO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5538
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 10203457
Estimated Expiration: ⤷  Start Trial

Patent: 14232475
Estimated Expiration: ⤷  Start Trial

Patent: 19200097
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2015020849
Estimated Expiration: ⤷  Start Trial

Patent: 1007025
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 44266
Estimated Expiration: ⤷  Start Trial

Patent: 42005
Estimated Expiration: ⤷  Start Trial

China

Patent: 2271665
Estimated Expiration: ⤷  Start Trial

Patent: 5073118
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 73295
Estimated Expiration: ⤷  Start Trial

Patent: 68363
Estimated Expiration: ⤷  Start Trial

Patent: 78368
Estimated Expiration: ⤷  Start Trial

Patent: 97762
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 0958
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 58812
Estimated Expiration: ⤷  Start Trial

Patent: 07711
Estimated Expiration: ⤷  Start Trial

Patent: 12514653
Estimated Expiration: ⤷  Start Trial

Patent: 15120700
Estimated Expiration: ⤷  Start Trial

Patent: 16514706
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 11007351
Estimated Expiration: ⤷  Start Trial

Patent: 15010594
Estimated Expiration: ⤷  Start Trial

Russian Federation

Patent: 22592
Estimated Expiration: ⤷  Start Trial

Patent: 15128028
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1507700
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 2238478
Estimated Expiration: ⤷  Start Trial

Patent: 150129671
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 73490
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1521731
Estimated Expiration: ⤷  Start Trial

Uruguay

Patent: 445
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TLANDO around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2012075081 ⤷  Start Trial
Argentina 095538 ⤷  Start Trial
Australia 2010203457 ⤷  Start Trial
Australia 2014232475 ⤷  Start Trial
Australia 2019200097 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.